Giulia Lorenzini
YOU?
Author Swipe
View article: Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey
Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey Open
Respiratory syncytial virus (RSV) causes respiratory infections across all ages, with an increasingly recognized burden in older adults, particularly those with comorbidities. Despite the recent licensure of RSV vaccines, awareness of RSV …
View article: 3P Evaluating conversational generative pre-trained transformer (ChatGPT) as a tool in early breast cancer (eBC) cases
3P Evaluating conversational generative pre-trained transformer (ChatGPT) as a tool in early breast cancer (eBC) cases Open
ChatGPT is a web interface chatbot based on a large language model with the aim to mimic human conversation tuned with machine learning and supervised techniques, that have gained scientific attention wondering if it can be a tool in medic…
View article: CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients Open
ESR1 mutations contribute to endocrine resistance and occur in a high percentage of hormone-receptor-positive (HR+) metastatic breast cancer (mBC) cases. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) changed the treatment landscape of H…
View article: Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib Open
View article: A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients Open
View article: Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients Open
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
View article: Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC Open
Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline-containing chemotherapy (CT) is currently the main systemic treat…
View article: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients Open
The present study demonstrates that concomitant use of PPIs in mBC patients treated with palbociclib has a detrimental effect on PFS. Therefore, it is recommended to prescribe PPIs with caution in these patients, strictly adhering to the i…
View article: 1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients
1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients Open
View article: Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre Open